CohBar, Inc. (CohBar) is engaged in the research and development of mitochondria-based therapeutics (MBTs), a class of drugs with potential for the treatment of diseases associated with aging. MBTs originate from the discovery of a group of peptides encoded within the genome of mitochondria. The Company's development of mitochondrial-derived peptides (MDPs) into MBTs offers the potential to address a range of diseases including type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders. MDPs represent a diverse and largely unexplored collection of peptides. MOTS-c is an MDP, which indicates that it plays a role in the regulation of metabolism. The Company is engaged in the research on MOTS-c and its analogs as its lead program. The Company's academic collaborators have discovered various other MDPs with similar mitochondrial origin to the MDP, humanin, which the Company refers to as small humanin-like peptides (SHLPs).